alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 520.154a Bacitracin methylenedisalicylate. ( a ) *Specifications.* Each pound of soluble powder contains the equivalent of 50 grams of bacitracin activity for use as in paragraph (d)(1) or (d)(2) of this section, or the equivalent of 200 grams of bacitracin activity for use as in paragraph (d) of this section.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Related tolerances.* See § 556.70 of this chapter.
( d ) *Conditions of use* — ( 1 ) *Broiler and replacement chickens* — ( i ) *Amount.* 100 mg per gal in drinking water. ( A ) *Indications for use.* Aid in the prevention of necrotic enteritis caused by *Clostridium perfringens* susceptible to bacitracin methylenedisalicylate.
( B ) *Limitations.* Prepare a fresh solution daily. Use as the sole source of drinking water.
( ii ) *Amount.* 200 to 400 mg per gal in drinking water. Administer continuously 5 to 7 days or as long as clinical signs persist, then reduce to prevention levels (100 mg/gal). ( A ) *Indications for use.* Treatment of necrotic enteritis caused by *C. perfringens* susceptible to bacitracin methylenedisalicylate.
( B ) *Limitations.* Prepare a fresh solution daily. Use as the sole source of drinking water.
( 2 ) *Growing turkeys* — ( i ) *Amount.* 400 milligrams (mg) per gallon (gal) in drinking water.
( ii ) *Indications for use.* Aid in the control of transmissible enteritis complicated by organisms susceptible to bacitracin methylenedisalicylate.
( iii ) *Limitations.* Prepare a fresh solution daily. Use as the sole source of drinking water.
( 3 ) *Swine* — ( i ) *Amount.* 1 gram per gallon in drinking water.
( ii ) *Indications for use.* Treatment of swine dysentery associated with *Brachyspira hyodysenteriae.* Administer continuously for 7 days or until signs of dysentery disappear.
( iii ) *Limitations.* Prepare a fresh solution daily. Use as the sole source of drinking water. Treatment not to exceed 14 days. Not to be given to swine that weigh more than 250 pounds.
( 4 ) *Growing quail* — ( i ) *Amount.* 400 mg per gal in drinking water.
( ii ) *Indications for use.* For prevention of ulcerative enteritis due to *Clostridium colinum* susceptible to bacitracin methylenedisalicylate.
( iii ) *Limitations.* Prepare fresh solution daily. Use as sole source of drinking water.
[57 FR 37322, Aug. 18, 1992; 57 FR 42623, Sept. 15, 1992, as amended at 63 FR 38474, July 17, 1998; 64 FR 13068, Mar. 17, 1999; 76 FR 53050, Aug. 25, 2011; 79 FR 28818, May 20, 2014; 80 FR 34278, June 16, 2015; 88 FR 14897, Mar. 10, 2023]
EXHIBIT 10.28
                                                                   -------------

                               ADDENDUM NUMBER ONE
                                       TO
                                RAMESH C. TRIVEDI
                            EMPLOYMENT CONTRACT DATED
                                December 8, 1995


Pursuant to actions taken by the Compensation Committee of the Board of
Directors of Integrated Surgical Systems, Inc. on December 18, 1997 and in the
months thereafter concluding on March 12, 1998, the following adjustments are to
be made in Dr. Trivedi's agreement.

     1.   Base Salary is to be increased by 6% from $22,000 per month to $23,320
          per month effective December 1, 1997.

     2.   Incentive base for 1998 is increased from $80,000 to $100,000. The
          actual payout amount will be based on the achievement against the 1998
          business plan agreed to by the board, with the calculation algorithm
          similar to the one used in 1997, but to be determined in fact at a
          later date.

     3,   Stock options for 100,000 shares are issued to Dr. Trivedi with a
          grant price of $4.75, the price of the stock on February 19, 1998. Of
          the 100,000 shares, the amount of shares that shall be immediately
          vested shall be 28,125. The balance of the shares, 71,875 shall vest
          ratably over the 48 month period beginning February 19, 1998.

     4.   Severance pay is currently set at 12 months in the event of
          termination of employment. As of this amendment, severance pay upon
          termination will be 18 months of Dr. Trivedi's base pay.

This amendment is incorporated and becomes a part of the Employment Contract
dated December 8, 1995. All other terms and conditions, not modified by this
agreement remain the same.


/s/ Ramesh C. Trivedi
----------------------------------                   ---------------------------
Ramesh C. Trivedi, President & CEO                   James C. McGroddy, Chairman

Date:  March 31, 1998                                Date:
       ---------------------------                         ---------------------
QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.94    
  


 
 

EXTENSION AGREEMENT    
  


Bank
of America, N.A.,

    as Administrative Agent

Attn: Suzanne Paul

231 South LaSalle Street

Chicago, Illinois 60604 


Ladies
and Gentlemen: 


        The
undersigned hereby agrees to extend, effective April 3, 2002, its Commitment and the Maturity Date under the Credit Agreement dated as of April 3, 2001 among
SOURCECORP, Incorporated, f/k/a F.Y.I. Incorporated, each of the Lenders party thereto, Bank of America, N.A., as Administrative Agent, and Banc of America Securities LLC, as sole lead arranger and
sole book agent (as the same may be amended or otherwise modified from time to time, the "Credit Agreement") for 364 days to April 2, 2005
pursuant to Section 2.1(d) of the Credit Agreement. Terms defined in the Credit Agreement are used herein as therein defined. 


        This
Extension Agreement shall be construed in accordance with and governed by the law of the State of Texas. The Extension Agreement may be signed in any number of counterparts, each of
which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. 



	

 	
 	
WELLS FARGO BANK TEXAS, NATIONAL

ASSOCIATION
	

 	
 	

Name:	

/s/ ZACH JOHNSON

	 	 	 	By:	Zach Johnson

	 	 	 	Title:	Vice President






	

Agreed and Accepted:
	

SOURCECORP, INCORPORATED, f/k/a

F.Y.I. INCORPORATED
	

By:	

/s/ BARRY EDWARDS

	Name:	Barry Edwards

	Title:	EVP & CFO

	

BANK OF AMERICA, N.A., as Administrative Agent
	

By:	

/s/ SUZANNE M. PAUL

	Name:	Suzanne M. Paul
	Title:	Vice President













QuickLinks



Exhibit 10.94


EXTENSION AGREEMENT
[ARTICLE] 5
[CIK] 0000814077
[NAME] ASSOCIATED PLANNERS REALTY GROWTH FUND
<TABLE>
<S>                             <C>
[PERIOD-TYPE]                   9-MOS
[FISCAL-YEAR-END]                          DEC-31-1995
[PERIOD-START]                             JAN-01-1995
[PERIOD-END]                               SEP-30-1995
[CASH]                                          15,726
[SECURITIES]                                         0
[RECEIVABLES]                                        0
[ALLOWANCES]                                         0
[INVENTORY]                                          0
[CURRENT-ASSETS]                                19,745
[PP&E]                                       3,591,500
[DEPRECIATION]                               (386,246)
[TOTAL-ASSETS]                               3,257,117
[CURRENT-LIABILITIES]                          450,790
[BONDS]                                      1,633,213
[COMMON]                                             0
[PREFERRED-MANDATORY]                                0
[PREFERRED]                                          0
[OTHER-SE]                                   1,183,008
[TOTAL-LIABILITY-AND-EQUITY]                 3,257,117
[SALES]                                        168,380
[TOTAL-REVENUES]                               174,986
[CGS]                                          179,893
[TOTAL-COSTS]                                  179,893
[OTHER-EXPENSES]                                     0
[LOSS-PROVISION]                                     0
[INTEREST-EXPENSE]                             113,922
[INCOME-PRETAX]                              (118,830)
[INCOME-TAX]                                         0
[INCOME-CONTINUING]                                  0
[DISCONTINUED]                                       0
[EXTRAORDINARY]                                      0
[CHANGES]                                            0
[NET-INCOME]                                 (118,830)
[EPS-PRIMARY]                                  (57.08)
[EPS-DILUTED]                                  (57.08)
</TABLE>
Editorial Note on Part 872
Editorial Note: Nomenclature changes to part 872 appear at 73 FR 35341, June 23, 2008.

§ 872.1 Scope. ( a ) This part sets forth the classification of dental devices intended for human use that are in commercial distribution.
( b ) The identification of a device in a regulation in this part is not a precise description of every device that is, or will be, subject to the regulation. A manufacturer who submits a premarket notification submission for a device under part 807 cannot show merely that the device is accurately described by the section title and identification provisions of a regulation in this part, but shall state why the device is substantially equivalent to other devices, as required by § 807.87.
( c ) To avoid duplicative listings, a dental device that has two or more types of uses (e.g., used both as a diagnostic device and as a therapeutic device) is listed in one subpart only.
( d ) References in this part to regulatory sections of the Code of Federal Regulations are to chapter I of title 21 unless otherwise noted.
( e ) Guidance documents referenced in this part are available on the Internet at *http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm .*
[52 FR 30097, Aug. 12, 1987, as amended at 68 FR 19737, Apr. 22, 2003; 79 FR 50552, Aug. 25, 2014]
# C_2014212EN.01003302.xml

| 7.7.2014 | EN | Official Journal of the European Union | C 212/33 |
| --- | --- | --- | --- |

7.7.2014

EN

Official Journal of the European Union

C 212/33

---

Action brought on 27 March 2014 — Hüpeden v Council and Commission

(Case T-206/14)

2014/C 212/43

Language of the case: German

Parties

Parties

Applicant: Hüpeden & Co. (GmbH & Co.) KG (Hamburg, Germany) (represented by: K. Landry, lawyer)

Applicant:

Defendants: Council of the European Union and European Commission

Defendants:

Form of order sought

Form of order sought

| — | Order the defendants to pay compensation to the applicant in the amount of EUR 1 18  762,57 together with interest at the rate of 8 % per annum from the date of delivery of the judgment, or to declare that the applicant is entitled to compensation from the defendants; |
| --- | --- |

—

Order the defendants to pay compensation to the applicant in the amount of EUR 1 18  762,57 together with interest at the rate of 8 % per annum from the date of delivery of the judgment, or to declare that the applicant is entitled to compensation from the defendants;

| — | Order the defendants to pay the costs. |
| --- | --- |

—

Order the defendants to pay the costs.

Pleas in law and main arguments

Pleas in law and main arguments

The applicant seeks compensation on account of the adoption of Regulation (EC) No 1355/2008, (1) which was declared invalid by judgment of the Court of Justice of 22 March 2012 in Case C-338/10 GLS.

1

GLS

The applicant submits that although the anti-dumping duties wrongly collected on the basis of that regulation have been refunded by the national customs authorities, it suffered financial loss as a result of the fact that it was compelled by the withdrawal of liquidity to obtain additional bank loans at the usual market rates of interest, as well as short-term fixed-rate loans. The applicant therefore seeks reimbursement of the difference between the interest it paid on its bank loans and the lower amount of interest that it would have had to pay if no anti-dumping duties had been collected. The applicant submits in that regard that, by unlawfully adopting Regulation No 1355/2008, the defendants committed a sufficiently serious breach of their duty of due care and proper administration, resulting in a loss to the applicant for which compensation is not otherwise available, since there is no provision under the relevant national rules on import duties for interest to be paid on the amount of any difference in favour of the person liable to pay import duties, from the time of payment.

---

(1)  Council Regulation (EC) No 1355/2008 of 18 December 2008 imposing a definitive anti-dumping duty and collecting definitively the provisional duty imposed on imports of certain prepared or preserved citrus fruits (namely mandarins, etc.) originating in the People’s Republic of China (OJ 2008 L 350, p. 35).

1

---
§ 807.90 Format of a premarket notification submission. Each premarket notification submission pursuant to this part shall be submitted in accordance with this section. Each submission shall: ( a ) ( 1 ) For devices regulated by the Center for Devices and Radiological Health, be addressed to the current address displayed on the website *https://www.fda.gov/cdrhsubmissionaddress .*
( 2 ) For devices regulated by the Center for Biologics Evaluation and Research, be addressed to the current address displayed on the website *https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CBER/ucm385240.htm ;* or for devices regulated by the Center for Drug Evaluation and Research, be addressed to the Central Document Room, Center for Drug Evaluation and Research, Food and Drug Administration, 5901-B Ammendale Rd., Beltsville, MD 20705-1266. Information about devices regulated by the Center for Biologics Evaluation and Research is available at *https://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/default.htm .*
( 3 ) All inquiries regarding a premarket notification submission should be sent to the address in this section or one of the current addresses displayed on the Food and Drug Administration's website.
( b ) [Reserved]
( c ) Be submitted as a single version in electronic format.
( d ) Be submitted separately for each product the manufacturer intends to market.
( e ) Designated “510(k) Notification” in the cover letter.
[42 FR 42526, Aug. 23, 1977, as amended at 53 FR 11252, Apr. 6, 1988; 55 FR 11169, Mar. 27, 1990; 65 FR 17137, Mar. 31, 2000; 70 FR 14986, Mar. 24, 2005; 75 FR 20915, Apr. 22, 2010; 80 FR 18094, Apr. 3, 2015; 84 FR 68339, Dec. 16, 2019]
Skip to main content 

U.S. Fish & Wildlife Service

## Utility (Top) navigation

-  About Us   **Forward **Back-  About Us
-  Mission & Vision
-  Leadership
-  Our Organization
-  Our Facilities
-  Regions

-  Laws & Regulations   **Forward **Back-  Laws & Regulations
-  Laws, Agreements & Treaties
-  Hunting Regulations

-  Library   **Forward **Back-  Library
-  Categories
-  Collections

                          -   Home 
                          -   Services   **Forward **Back-   Services 
-   Duck Stamps   **Forward **Back-   Duck Stamps 
-   Buy a Duck Stamp or E-Stamp 
-   Buy a Junior Duck Stamp 

-   Fish Stocking 
-   Importing & Exporting 
-   Consultation & Technical Assistance   **Forward **Back-   Consultation & Technical Assistance 
-   ESA Section 7 Consultation 
-   Habitat Conservation Planning (HCPs) 
-   Candidate Conservation Agreements (CCA & CCAA) 
-   Safe Harbour Agreements (SHA) 
-   Conservation Banking 
-   Coastal Barrier Resources Act Project Consultation 
-   Coastal Barrier Resources System Property Documentation 

-   Financial Assistance 
-   Species Management 
-   Investigational New Animal Drugs (INADS) 
-   Permits 
-   Search All Services 
Duck StampsOne of the easiest ways that anyone can support bird habitat conservation is by buying duck stamps.
                          -   Species   **Forward **Back-   Species 
-   Explore Taxonomic Tree 
-   Find a Species 
Interest storyBats: “The Coolest Mammals on Earth”
                          -   Visit Us   **Forward **Back-   Visit Us 
-   Events 
-   National Fish Hatcheries 
-   National Wildlife Refuges 
-   Outdoor Recreation 
-   Recreation Passes 
-   Our Locations 
Scenic DrivesTour routes of great scenic drives on National Wildlife Refuges.
                          -   Get Involved   **Forward **Back-   Get Involved 
-   Careers and Internships 
-   Volunteering 
-   Friends Partnerships 
-   Learning Opportunities 
-   Education Programs 
-   Events 
-   Partnerships   **Forward **Back-   Partnerships 
-   Partnership Categories 
-   Partner List 

VolunteerSearch for volunteer opportunities around the country
                          -   Newsroom   **Forward **Back-   Newsroom 
-   Press Releases 
-   Congressional Testimony 
-   Media Contacts 
Wild ThingsNews about wonderful wild things and places
                          -   Initiatives   **Forward **Back-   Initiatives 
-   Combating Wildlife Trafficking 
-   Director's Priorities 
-   Climate Change 
-   Hunting 
-   Fishing 
-   Invasive Species 
-   Pollinators 
-   Protecting Wildlife 
Climate ActionFWS is taking steps to mitigate climate impacts
                          -   I want to   **Forward **Back-  I Want To
-   Report Wildlife Crime 
-   Do Business with FWS 
-   Volunteer 
-   Find a Job or Internship 
-   Visit a Refuge 
-   Buy a Duck Stamp 
-   Apply for a Permit 
-   Find Funding 
-   Find Training 
Wild workSearch employment opportunities with USFWS

## Search

Search

# Cokeville Meadows National Wildlife Refuge
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONSOLIDATED FINANCIAL STATEMENTS OF ENTREE CORPORATION AS OF AND FOR THE 28
WEEKS ENDED OCTOBER 12, 1996 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO
SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          MAR-29-1997
<PERIOD-START>                             MAR-31-1996
<PERIOD-END>                               OCT-12-1996
<CASH>                                            1413
<SECURITIES>                                         0
<RECEIVABLES>                                     9885
<ALLOWANCES>                                     (350)
<INVENTORY>                                       5153
<CURRENT-ASSETS>                                 16664
<PP&E>                                            7789
<DEPRECIATION>                                  (4706)
<TOTAL-ASSETS>                                   20135
<CURRENT-LIABILITIES>                            14456
<BONDS>                                            765
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            80
<OTHER-SE>                                      (2566)
<TOTAL-LIABILITY-AND-EQUITY>                     20135
<SALES>                                         130868
<TOTAL-REVENUES>                                130870
<CGS>                                           128827
<TOTAL-COSTS>                                   128827
<OTHER-EXPENSES>                                  2099
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 473
<INCOME-PRETAX>                                  (508)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                              (508)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                  (227)
<CHANGES>                                            0
<NET-INCOME>                                     (735)
<EPS-PRIMARY>                                    (.09)
<EPS-DILUTED>                                    (.09)
        

</TABLE>
NUMBER 13-13-00280-CV

COURT OF APPEALS

THIRTEENTH DISTRICT OF TEXAS

CORPUS CHRISTI - EDINBURG

____________________________________________________________

IN THE INTEREST OF C.G.B.R., A CHILD

____________________________________________________________

On Appeal from the 206th District Court 

of Hidalgo County, Texas.

____________________________________________________________

MEMORANDUM OPINION

Before Chief Justice Valdez and Justices Rodriguez and Garza

Memorandum Opinion Per Curiam

Appellant, Leonardo Ruiz, perfected an appeal from a judgment entered by the 

206th District Court of Hidalgo County, Texas, in cause number F-3483-08-D. Appellant 

has filed an amended unopposed motion to dismiss the appeal on grounds that he no 

longer wishes to pursue the appeal. Appellant requests that this Court dismiss the 

appeal.

The Court, having considered the documents on file and appellant’s motion to 

dismiss the appeal, is of the opinion that the motion should be granted. See TEX. R. APP.
2

P. 42.1(a). Appellant’s motion to dismiss is granted, and the appeal is hereby 

DISMISSED. In accordance with the agreement of the parties, costs are taxed against 

the party incurring same. See TEX. R. APP. P. 42.1(d) ("Absent agreement of the parties, 

the court will tax costs against the appellant."). Having dismissed the appeal at 

appellant's request, no motion for rehearing will be entertained, and our mandate will 

issue forthwith.

PER CURIAM

Delivered and filed the 24th

day of October, 2013.
Exhibit 32.1



Certification Pursuant to § 906 of the Sarbanes-Oxley Act of 2002



Pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the
Sarbanes-Oxley Act of 2002, in connection with the filing of the Form 10-Q of STERIS Corporation (the Company) for the quarter ended September 30, 2005, as filed with the Securities and Exchange Commission on the date hereof (the
Report), each of the undersigned officers of the Company certifies, that, to such officers knowledge:



| | (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | --- | ---------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the
periods expressed in the Report.
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



/s/    LES C.
VINNEYName:

Les C. VinneyTitle:

President and Chief Executive Officer (Principal Executive Officer)/s/    LAURIE BRLASName:

Laurie BrlasTitle:

Senior Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)




Dated: November 9, 2005